OMNIQ Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that OMNIQ Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.72M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $34.88M | Apr 15, 2026 |
| FY2017 | Dec 31, 2017 | $54.46M | May 8, 2018 |
| FY2017 | Dec 31, 2016 | $60.05M | May 8, 2018 |
| FY2016 | Dec 31, 2015 | $58.60M | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $37.31M | Apr 18, 2016 |
| FY2014 | Dec 31, 2013 | $4.1K | Apr 9, 2015 |
| FY2013 | Dec 31, 2012 | $1.2K | Apr 2, 2014 |
| FY2012 | Dec 31, 2011 | $36.8K | Apr 12, 2013 |
| FY2011 | Dec 31, 2010 | $182.2K | Apr 19, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.95M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $34.88M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $81.19M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $100.76M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $78.25M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $55.21M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $57.20M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $56.20M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $54.46M | Jun 5, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $2.0K | Apr 2, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.04M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $5.63M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $15.71M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $22.10M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $16.67M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $10.92M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $14.03M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $13.06M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $11.37M | Jun 5, 2019 |
| FY2017 | Dec 31, 2016 | $12.09M | May 8, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($137.0K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($10.00M) | Apr 15, 2026 |
| FY2023 | Dec 31, 2023 | ($29.43M) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($13.68M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($13.36M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($11.50M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($5.46M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($5.22M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($2.43M) | Jun 5, 2019 |
| FY2017 | Dec 31, 2016 | ($14.35M) | May 8, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.85M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($6.62M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($26.20M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($9.55M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($10.48M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($8.98M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.86M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($3.02M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($878.5K) | Jun 5, 2019 |
| FY2017 | Dec 31, 2016 | ($1.19M) | May 8, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.02M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.85M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.15M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.83M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.87M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.81M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.06M | Mar 31, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.82M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $9.14M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $22.96M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $27.71M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $21.87M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $15.80M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $13.68M | Mar 31, 2021 |
| FY2013 | Dec 31, 2013 | $11.4K | Apr 2, 2014 |
| FY2013 | Dec 31, 2012 | $4.6K | Apr 2, 2014 |
| FY2012 | Dec 31, 2011 | $14.8K | Apr 12, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.50M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $2.37M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $170.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.20M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.18M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($420.0K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.26M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.70M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $7.49M | Jun 5, 2019 |
| FY2017 | Dec 31, 2016 | $5.65M | May 8, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $42.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $479.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $451.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $299.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.0K | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | $134.0K | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $29.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $17.2K | Jun 5, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.18M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $43.59M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $39.49M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $64.81M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $75.08M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $38.66M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $34.45M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $40.15M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $26.06M | Jun 5, 2019 |
| FY2017 | Dec 31, 2016 | $32.79M | May 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.87M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $87.48M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $74.51M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $75.34M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $72.78M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $43.70M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $32.62M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $37.86M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $27.30M | Jun 5, 2019 |
| FY2017 | Dec 31, 2016 | $47.62M | May 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.70M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($43.89M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($35.02M) | Apr 15, 2026 |
| FY2023 | Dec 31, 2022 | ($10.53M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($98.0K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($5.04M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.81M | Mar 31, 2021 |
| FY2020 | Dec 31, 2018 | $2.52M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | ($1.25M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | ($14.83M) | Jun 5, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.34M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $2.92M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $1.79M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $16.54M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $16.45M | Apr 1, 2024 |
| FY2021 | Dec 31, 2020 | $14.70M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $13.92M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $13.92M | Mar 30, 2020 |
| FY2019 | Oct 5, 2018 | $3.81M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $10.11M | Jun 5, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($124.05M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($123.90M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($113.92M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($84.46M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($70.57M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($56.73M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($45.06M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($39.75M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($35.55M) | Jun 5, 2019 |
| FY2017 | Dec 31, 2016 | ($32.94M) | May 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $679.0K | Apr 15, 2026 |
| FY2025 | Jul 11, 2025 | $2.39M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $2.35M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.68M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.31M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.09M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.13M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.62M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $378.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $24.6K | Jun 5, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $1.12M | Mar 31, 2021 |
| FY2015 | Dec 31, 2015 | $1.82M | Apr 18, 2016 |
| FY2013 | Dec 31, 2013 | $1.98M | Apr 2, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | (2) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | (1) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | (2) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Jun 5, 2019 |
| FY2017 | Dec 31, 2016 | 0 | May 8, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 31, 2025 |
| FY2020 | Dec 31, 2020 | (2) | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | (1) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | (2) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Jun 5, 2019 |
| FY2017 | Dec 31, 2016 | 0 | May 8, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Apr 18, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15.10M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 10.71M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 10.68M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 7.71M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 7.46M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 4.68M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 3.96M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 3.60M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 36.83M | Jun 5, 2019 |
| FY2017 | Dec 31, 2016 | 35.10M | May 8, 2018 |